SCORE Study Results of MammaTyper® LRP Model in HR+/HER2− Breast Cancer Presented at ECP 2026

BERLIN, GERMANY, September 17, 2026 /EINPresswire.com/ -- Cerca Biotech announced the presentation of promising findings from the SCORE study by investigators at the 2026 European Congress of Pathology (ECP), demonstrating the potential of the MammaTyper® Low-Risk Prediction (LRP) model as a cost effective locally available testing tool to identify HR+/HER2− breast cancer patients having an Oncotype DX® Recurrence Score of ≤25.

> These findings support the potential of MammaTyper® LRP as a locally available low cost molecular pre-screen for identifying patients having an Oncotype DX® RS ≤25 who are at low recurrence risk."
>
> *Rich Hughes, Commercial Director of Cerca Biotech*

The multicenter, retrospective study, conducted by investigators from Vall d'Hebron University Hospital, Virgen de la Victoria University Hospital, and Malaga Biomedical Research Institute in Spain, evaluated 211 archived breast cancer tissue samples from patients with previous Oncotype DX® Recurrence Score results. MammaTyper® LRP, calculated from ESR1, PGR, and MKI67 mRNA expression, can identify, with a positive predictive value of 95%, patients classified as low recurrence risk by Oncotype DX® (RS ≤25), who are unlikely to benefit from chemotherapy.

This study confirms the previously presented results of a multicenter study conducted in Germany (H-A Lehr, et al., 2019). In addition, it is also consistent with a recently published Chinese retrospective study showing that MammaTyper® LRP score is an independent prognostic factor in early stage HR+/HER2− breast cancer, and patients classified as LRP low risk derive no benefit from adjuvant chemotherapy (Ding M, et al., 2026).

"These findings support the potential of MammaTyper® LRP as a locally available low cost molecular pre-screen for identifying patients having an Oncotype DX® RS ≤25 who are at low recurrence risk," said Rich Hughes, Cerca Biotech's Commercial Director. "We are encouraged by the results of the SCORE study and by the potential of MammaTyper® to become a widely accessible, cost effective, and versatile molecular tool for improving personalized precision treatment of breast cancer."

References:
1. Correlation of RT-qPCR–based progesterone receptor, estrogen receptor, and Ki-67 expression with multigene recurrence risk in hormone receptor–positive/HER2-negative breast cancer (SCORE study). ECP 2026. (https://ecp2026.abstractserver.com/programme/#/scientific/details/presentations/1545)
2. H-A Lehr, et al., Standardized prediction of Oncotype DX® risk classes by local RT-qPCR. Cancer Res. 2019;79 (4_Supplement): P2-07-08. doi:10.1158/1538-7445.SABCS18-P2-07-08
3. Ding M, et al., Clinical validation of the MammaTyper® LRP model for identification of low risk patients with early-stage ER+/HER2- breast cancer: from subtyping to chemotherapy de-escalation, Clinical Breast Cancer. Available online 24 August 2026
4. MammaTyper® is a trademark of Shuwen Biotech. Oncotype DX® is a trademark of Exact Sciences Inc.

About MammaTyper®
MammaTyper® is an innovative assay for the quantitative determination of the four key biomarkers used in the subtyping of breast cancer (Human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR) and Ki-67). Applying sensitive and quantitative RT-qPCR techniques, it is a quick, accurate, reliable, and reproducible solution that enables medical professionals to accurately tailor treatment plans for the best chance of success. Further information on MammaTyper® is available at https://cercabiotech.com/product/mammatyper/.

About Cerca Biotech
Cerca Biotech is a diagnostic company based in Germany focused on bringing novel and innovative diagnostic products to the oncology and women's health market. We strive to introduce the best tests to meet the unmet clinical needs at an affordable cost, with clinical accuracy and rapid results as our focus. Utilising a combination of experienced distributors and direct sales Cerca Biotech has a commercial reach from Germany through the Nordics and Eastern Europe to the Middle East, Africa, India and beyond. Our team comprises of highly experienced commercial, technical and clinical experts in the field of IVD, allowing rapid deployment of novel technologies with a "get it right first time" strategy.

For more information, visit the company website at www.cercabiotech.com or contact info@cercabiotech.com

Richard Hughes
Cerca Biotech GmbH
email us here
Visit us on social media:
LinkedIn
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/942660284

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.